Phase 2 Development Sample Clauses

Phase 2 Development. Image Maintenance ● Client will provide export of image or distribution point server to access image. ● Insight will perform initial Image Update setup work. ● Quarterly Image Update can include the following maintenance modifications: o Critical operating system updates;
Sample 1
AutoNDA by SimpleDocs
Phase 2 Development. The Phase 2 development under this SOW shall use the same RF chip and ATC Baseband chip as Phase 1. In Phase 2 Development, the ASIC development can begin once the foundry is selected for fabrication. The ASIC development process includes design, verification, physical design and fabrication. The ASIC prototypes shall be provided to Contractor for placement on the Oberon Integration Board. The ASIC shall be verified using Contractor diagnostic releases on the Oberon Integration Board in combination with the Phase 1 Macro Board. At the completion of the diagnostic integration, the Contractor shall carry out a DVT to validate all performance and functional attributes of the Phase 2 chipset platform. At this point, pre-production parts will be available. The Contractor shall then be responsible for integration and test of the satellite portion, including all mobility functionality, with the S-BSS in a lab environment. TerreStar shall support this integration and test as necessary to resolve issues that arise. After DVT, the Contractor will also carry out DQT after which the production ASICs will be made available to TerreStar. [***]
Sample 1
Phase 2 Development. Foliofn Investments, Inc. may, at its sole discretion, decide to host and manage the secondary note trading platform for Prosper as part of a phase 2 development efforts. Preliminary cost estimates to develop said platform are projected to be approximately $240,000. Upon receipt of written notice from Foliofn anytime during the term of this agreement, Prosper agrees to contribute up to 50% of the projected development expense not to exceed $120,000, provided however that Prosper shall not be obligated to contribute toward any projected expenses that are not approved by Prosper prior to expenditure, provided however that Prosper shall have the ability to review and approve all projected expense items, which approval will not be unreasonably or untimely withheld. Payment for development would be pro-rated across the estimated development time schedule. In the event of a phase 2 development, both parties agree to amend the existing hosting agreement to reflect all necessary changes related to Foliofn managing the secondary market platform on behalf of Prosper.
Sample 1
Phase 2 Development. The Developer intends to conduct the Phase 2 development on Parcel B of Lot 1 in the attached Exhibit 1 within five (5) years from obtaining title to Lot 1. If the Developer fails to take substantial steps toward development, including but not limited to submitting development plans for the City’s approval, of said Parcel B of Lot 1 within five (5) years of taking title to the property, said Parcel B shall be transferred back to the City at no additional cost to the City. In such event, the City shall not be responsible for any costs, expenses, damages, time, or other damages incurred as a result of Developer’s failure to complete Phase 2 of the development.
Sample 1
Phase 2 Development 
Sample 1

Related to Phase 2 Development

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Information Systems Acquisition Development and Maintenance Security of System Files. To protect City Information Processing Systems and system files containing information, Service Provider will ensure that access to source code is restricted to authorized users whose specific job function necessitates such access.

  • Independent Development Receiving Party may currently or in the future be developing information internally, or receiving information internally, or receiving information from other parties that may be similar to the Disclosing Party's Confidential Information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Receiving Party will not develop or have developed products or services, that, without violation of this Agreement, might compete with the products or systems contemplated by the Disclosing Party's Confidential Information.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.